Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353709 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL392505 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL12291433 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL846295 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708932 | 0.98 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708931 | 0.98 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Fumaric Acid SCHEMBL29353244 | 0.92 | DPP4 (0.84) | DPP4DPP7DPP8DPP9 | |
| Fumaric Acid SCHEMBL21638348 | 0.92 | DPP4 (0.84) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL28071368 | 0.90 | DPP4 (0.82) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL28071366 | 0.90 | DPP4 (0.82) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| EP-3199203-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2020-02-05 | — | — | EP | claimed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| EP-3199203-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | BALKAN BORK (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | BALKAN BORK (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120015029-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | PFEFFER SABINE (DE) | 2012-01-19 | — | — | US | disclosed |
| EP-1658066-B9 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1658066-B1 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2009-09-30 | — | — | EP | disclosed |
| US-20080300293-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | WANG PEI-RAN | 2008-12-04 | — | — | US | disclosed |
| US-20080300293-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | WANG PEI-RAN | 2008-12-04 | — | — | US | disclosed |
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | BALKAN BORK | 2008-03-27 | — | — | US | disclosed |
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | BALKAN BORK | 2008-03-27 | — | — | US | disclosed |
| CN-101115740-A | Treatment of substituted pyridyl and pyrimidinyl derivatives and related diseases as metabolic modulators | ARENA PHARM INC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1743655-A1 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| EP-1741447-A2 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| EP-1741445-A2 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| EP-1741446-A2 | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | Novartis AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004052362-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | G6PC1, GCK, PDK4 | DPP4 17/4885DPP7 28/4885DPP8 36/4885 |
| US-20120015029-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20080300293-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | PPARG, DPP4, FABP4 | DPP4 2/4885DPP7 18/4885DPP8 17/4885 |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 4/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885DPP7 2/4885DPP8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.